Nemes Rush Group LLC Sells 3,385 Shares of Moderna, Inc. (NASDAQ:MRNA)

Nemes Rush Group LLC decreased its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 38.4% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 5,437 shares of the company’s stock after selling 3,385 shares during the quarter. Nemes Rush Group LLC’s holdings in Moderna were worth $541,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Arlington Trust Co LLC boosted its position in shares of Moderna by 4,833.3% during the 4th quarter. Arlington Trust Co LLC now owns 296 shares of the company’s stock valued at $29,000 after acquiring an additional 290 shares in the last quarter. Archer Investment Corp lifted its stake in Moderna by 71.2% during the third quarter. Archer Investment Corp now owns 534 shares of the company’s stock worth $55,000 after purchasing an additional 222 shares during the period. Parkside Financial Bank & Trust lifted its stake in Moderna by 44.9% during the third quarter. Parkside Financial Bank & Trust now owns 565 shares of the company’s stock worth $58,000 after purchasing an additional 175 shares during the period. Sachetta LLC bought a new position in Moderna during the fourth quarter worth about $56,000. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA lifted its stake in Moderna by 408.3% during the third quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 610 shares of the company’s stock worth $63,000 after purchasing an additional 490 shares during the period. Institutional investors own 75.33% of the company’s stock.

Insiders Place Their Bets

In other Moderna news, CFO James M. Mock sold 647 shares of the business’s stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $94.57, for a total transaction of $61,186.79. Following the sale, the chief financial officer now directly owns 4,300 shares of the company’s stock, valued at approximately $406,651. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other news, President Stephen Hoge sold 2,388 shares of the company’s stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $94.57, for a total value of $225,833.16. Following the sale, the president now directly owns 1,515,898 shares of the company’s stock, valued at approximately $143,358,473.86. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO James M. Mock sold 647 shares of the company’s stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $94.57, for a total transaction of $61,186.79. Following the completion of the sale, the chief financial officer now directly owns 4,300 shares in the company, valued at $406,651. The disclosure for this sale can be found here. Insiders have sold 170,209 shares of company stock valued at $18,588,421 in the last three months. 15.20% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of brokerages have commented on MRNA. Evercore ISI began coverage on shares of Moderna in a research note on Tuesday, May 14th. They set an “in-line” rating and a $120.00 price target for the company. Jefferies Financial Group restated a “buy” rating and set a $125.00 price target on shares of Moderna in a research note on Tuesday, April 9th. Oppenheimer raised their price target on shares of Moderna from $142.00 to $163.00 and gave the stock an “outperform” rating in a research note on Friday, May 3rd. UBS Group lifted their target price on shares of Moderna from $143.00 to $151.00 and gave the company a “buy” rating in a research note on Tuesday, May 7th. Finally, Canaccord Genuity Group lifted their target price on shares of Moderna from $91.00 to $106.00 and gave the company a “hold” rating in a research note on Friday, May 3rd. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and six have given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $126.46.

Moderna Trading Up 10.1 %

Shares of MRNA stock traded up $14.55 on Wednesday, hitting $158.24. The stock had a trading volume of 6,750,736 shares, compared to its average volume of 4,082,843. The firm has a market cap of $60.64 billion, a P/E ratio of -9.89 and a beta of 1.57. Moderna, Inc. has a twelve month low of $62.55 and a twelve month high of $160.89. The company has a fifty day moving average price of $112.02 and a two-hundred day moving average price of $98.83. The company has a current ratio of 4.03, a quick ratio of 3.91 and a debt-to-equity ratio of 0.04.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings data on Thursday, May 2nd. The company reported ($3.07) EPS for the quarter, beating the consensus estimate of ($3.59) by $0.52. The business had revenue of $167.00 million for the quarter, compared to analysts’ expectations of $93.26 million. Moderna had a negative net margin of 115.82% and a negative return on equity of 20.10%. The firm’s revenue was down 91.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.19 EPS. As a group, analysts forecast that Moderna, Inc. will post -7.5 earnings per share for the current fiscal year.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.